Drug Profile
TP 6076
Alternative Names: TP-6076Latest Information Update: 01 Apr 2022
Price :
$50
*
At a glance
- Originator Tetraphase Pharmaceuticals
- Class Amides; Amines; Antibacterials; Ethers; Fluorinated hydrocarbons; Fluorobenzenes; Pyrrolidines; Tetracyclines
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Gram-negative infections
Most Recent Events
- 28 Jul 2020 Tetraphase Pharmaceuticals has been acquired by La Jolla Pharmaceutical Company
- 31 Dec 2019 Tetraphase Pharmaceuticals completes a phase I trial in Healthy volunteers
- 31 Dec 2019 Tetraphase Pharmaceuticals completes the phase I single and multiple ascending dose trials in Healthy volunteers